

Complete Listing of the Claims

Claims 1-40 (cancelled)

41. (previously presented) A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a therapeutically effective amount of *N*-{2-[4-(3-phenyl-4-methoxyphenyl)aminophenyl]ethyl}-(*R*)-2-hydroxy-2-(8-hydroxy-2(1*H*)-quinolinon-5-yl)ethylamine or a pharmaceutically-acceptable salt thereof.

42. (previously presented) The pharmaceutical composition of Claim 41, wherein the composition is formulated for administration by inhalation.

43. (previously presented) The pharmaceutical composition of Claim 41 wherein the composition further comprises a therapeutically effective amount of a steroidal anti-inflammatory agent.

44. (previously presented) The pharmaceutical composition of Claim 43, wherein the composition is formulated for administration by inhalation.

45. (previously presented) The pharmaceutical composition of Claim 41, wherein the composition further comprises a therapeutically effective amount of one or more therapeutic agents selected from the group consisting of a steroidal anti-inflammatory agent, a muscarinic receptor antagonist agent, a phosphodiesterase inhibitor agent, an immunoglobulin antibody, a leukotriene antagonist agent, a cytokine antagonist agent, a protease inhibitor, cromolyn sodium, nedocromil sodium, and sodium cromoglycate.

46. (previously presented) A method of treating a disease or condition in a mammal associated with  $\beta_2$  adrenergic receptor activity, the method comprising administering to the mammal, a therapeutically effective amount of a pharmaceutical composition of Claim 41.

47. (previously presented) The method of Claim 46 wherein the disease or condition is a pulmonary disease.

48. (previously presented) The method of Claim 47 wherein the pulmonary disease is asthma or chronic obstructive pulmonary disease.

49. (previously presented) The method of Claim 46 wherein the disease or condition is selected from the group consisting of pre-term labor, neurological disorders, cardiac disorders, and inflammation.

50. (previously presented) The method of Claim 46 further comprising administering a therapeutically effective amount of a steroidal anti-inflammatory agent.

51. (previously presented) The method of Claim 46 further comprising administering a therapeutically effective amount of one or more therapeutic agents selected from the group consisting of a steroidal anti-inflammatory agent, a muscarinic receptor antagonist agent, a phosphodiesterase inhibitor agent, an immunoglobulin antibody, a leukotriene antagonist agent, a cytokine antagonist agent, a protease inhibitor, cromolyn sodium, nedocromil sodium, and sodium cromoglycate.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**